Oncología médica - Open Access .click

Results 51 to 60 of about 25,814 (203)

Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors

Redox Biology, 2015
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are overexpressed in the majority of renal cell carcinomas (RCC). This characteristic has supported the rationale of targeting VEGF-driven tumour vascularization, especially in clear cell
Luís A. Leon, Luís M. Antón-Aparicio
doaj +1 more source

Predicting Different Recurrence Risk in HNSCC Using Circulating Inflammatory and T‐Cell Biomarkers

The Laryngoscope, Volume 136, Issue 5, Page 2189-2198, May 2026.
ABSTRACT Objective Head and neck squamous cell carcinoma (HNSCC) lacks reliable prognostic circulating biomarkers, and the role of the immune system in its progression remains incompletely understood. This study aimed to evaluate the prognostic value of systemic inflammatory and immune biomarkers in surgically treated patients with primary oral cavity (
Riccardo Gili +10 more
wiley +1 more source

SÃndrome Doege-Potter secundario a tumor fibroso solitario pulmonar. A propÃ³sito de un caso

Gaceta Mexicana de Oncología, 2023
El tumor fibroso solitario es una neoplasia poco frecuente. La asociación de hipoglucemia como manifestación paraneoplásica se conoce como síndrome de Doege-Potter. Es una entidad clínica muy poco frecuente y de difícil diagnóstico.
Amelia Muñoz-Lerma +3 more
doaj +1 more source

Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples

Cytopathology, Volume 37, Issue 3, Page 275-283, May 2026.
The study evaluates the use of residual liquid‐based cytology (LBC) samples from pancreatic ductal adenocarcinoma (PDAC) for molecular analysis. It shows that LBC samples preserve nucleic acid quality and remain suitable for next‐generation sequencing (NGS) and MSI testing even after prolonged storage, underscoring their value when other samples are ...
Raquel Antón‐Peñalver +17 more
wiley +1 more source

Evolución epidemiológica del cáncer de ovario en España y el resto de Europa: revisión bibliográfica [PDF]

, 2019
Los tumores ováricos son la cuarta causa de muerte por cáncer femenino en España, donde se diagnostican cerca de 3000 casos anuales y la tasa de mortalidad supera el 50%.
Poncio Rodero, Paula
core

Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR‐HCC (Lombardy Real‐World HCC Group)

Liver International, Volume 46, Issue 5, May 2026.
ABSTRACT Background and Aim Dual immune checkpoint blockade with tremelimumab plus durvalumab (STRIDE) is an established first‐line therapy for unresectable hepatocellular carcinoma (uHCC); however, real‐world evidence on its safety, toxicity kinetics and liver function dynamics remains limited.
Andrea Casadei‐Gardini +27 more
wiley +1 more source

Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients

Scientific Reports, 2021
SARS-CoV-2 infection increases the risk of thrombosis by different mechanisms not fully characterized. Although still debated, an increase in D-dimer has been proposed as a first-line hemostasis test associated with thromboembolic risk and unfavorable ...
María Eugenia de la Morena-Barrio +10 more
doaj +1 more source

Association Between Colorectal Cancer Screening and Survival in Patients Older Than 70 Years: Results of A National Multicenter Retrospective Study

Journal of Surgical Oncology, Volume 133, Issue 5, Page 572-579, April 2026.
ABSTRACT Background Colorectal cancer screening mainly targets a population between 50 and 70 years of age; however, it is inconsistently implemented in people over 70. The aim of this study was to analyze the association between colorectal cancer (CRC) screening, postoperative mortality, and perioperative and oncologic outcomes in a large population ...
Matteo Rottoli +499 more
wiley +1 more source

Después de muchos años: los tiempos de espera en oncología [PDF]

, 2003
Sin ...
Bayés, Ramón
core +2 more sources

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate‐1‐Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Ruxolitinib (RUX), a JAK1/2 inhibitor, demonstrated treatment benefits for myelofibrosis (MF) in intermediate‐1 (Int‐1)–risk patients with a significant disease burden; however, the evidence is scarce. This interim analysis investigated the efficacy and safety of ruxolitinib in patients with Int‐1‐risk MF.
Paola Guglielmelli +55 more
wiley +1 more source

humanities
medicine
philosophy

art
gynecology
political science

internal medicine
psychology
computer science